" Martin is a rare professional with commercial nose, and the ability to think in a creative and visionary way. I enjoyed working with Martin for over 3 years at Tillotts Pharma as a colleague. I was impressed with Martin's ability to drive new growth opportunities with tenacity and passion whilst applying his solid financial management, data analysis, and communication skills. I highly recommend Martin who would be a great asset to a team. "
Dateien in Kürze verfügbar.
"It has always been a pleasure to work with Martin. He has a very professional attitude and a keen business sense. And with his open-mindedness and pragmatic way to look at things he always finds the best solution in difficult situations. Martin is a strong and fair negotiator which has been of great value for the company resulting in agreements of high impact. But what I like the most about him is that he really cares about the people around him. "
"I had the pleasure to work with Martin on projects related to geographic expansion and partnership with distributors. Martin has always shown a great business acumen, mastering the alliance management and fostering a culture of collaboration. Martin has always been able to adapt his leadership style according to the complexity of the situation thus avoiding projects might have derailed. Noteworthy he has always been respectful of the cross-functional team's members competencies and has been able to drive the team to success. I have personally found his leadership being mirrored in the great attitude of his team. "
Martin provided an insightful presentation on Business Development and Licensing in Europe for the Korean visitors of Basel Area Innovation Park. The participants are senior managers, CEOs and founders of Biotech, MedTech business, and the Korean pharmaceutical association. Feedback and Question and answers indicated interest was quite substantial. This is the first step for deeper and broader business development assessment for these companies, venturing into Europe. The presentation is logically structured, relevant to EU BDL, and very well explained. Some examples of real-life licensing histories made it easier to understand, and more engaging.
Through the consultancy we realized in which stage we are developing a vaccine in human health, i.e. how our vaccine platform is valued by externals. Marvapharm was very quickand very accurate in delivering the required results
Our benefits in summary;